AOM in children

Search date September 2010
Roger A J M Damoiseaux and Maroeska M Rovers

ABSTRACT

INTRODUCTION: In the UK, about 30% of children under 3 years of age visit their GP each year with acute otitis media (AOM), and 97% of these receive antibiotics. In the US, AOM is the most common reason for outpatient antibiotic treatment. Without antibiotics, AOM resolves within 24 hours in about 60% of children, and within 3 days in about 80% of children. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for AOM in children; and what are the effects of interventions to prevent recurrence? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 29 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics, antibiotics, delayed antibiotics, immediate antibiotics, long-term antibiotic prophylaxis, longer courses of antibiotics, myringotomy, pneumococcal vaccination, tympanostomy with ventilation tubes, xylitol syrup or gum, and influenza vaccination.

QUESTIONS

What are the effects of treatments for AOM in children? .......................................................... 3
What are the effects of interventions to prevent recurrence of AOM in children? .......................... 18

INTERVENTIONS

TREATMENTS FOR AOM IN CHILDREN

 Likely to be beneficial
Analgesics ................................................. 3

 Trade off between benefits and harms
Antibiotics (reduce symptoms more quickly than placebo but increase adverse effects) ............... 6
Choice of antibiotic regimen ........................................... 9
Immediate compared with delayed antibiotic treatment ....................................................... 11
Longer courses of antibiotics (reduce treatment failure in the short term but not the long term) .......... 13

 Likely to be ineffective or harmful
Myringotomy .................................................. 15

 PREVENTING RECURRENCE OF AOM IN CHILDREN

 Likely to be beneficial
Pneumococcal vaccine .................................................. 19

Trade off between benefits and harms
Antibiotic prophylaxis (long term) ................................. 18

Unlikely to be beneficial
Influenza vaccine New ........................................... 23
Xylitol syrup or gum New ............................................ 24

Likely to be ineffective or harmful
Tympanostomy (ventilation tubes) ................................. 21

Covered elsewhere in Clinical Evidence
See chronic suppurative otitis media
See otitis media with effusion

Key points

- AOM is characterised by sudden onset of earache with a cloudy or bulging erythematous eardrum caused by middle-ear infection.

  Middle-ear effusion without signs of infection lasting >3 months suggests otitis media with effusion (‘glue ear’), while chronic suppurative otitis media is characterised by continuing middle-ear inflammation and discharge through a perforated eardrum. These disorders are assessed in separate reviews in Clinical Evidence.

  The most common pathogens in AOM in the US and UK are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

  In the UK, about 30% of children under 3 years of age visit their GP each year with AOM, and 97% of these receive antibiotics. In the US, AOM is the most common reason for outpatient antibiotic treatment.

- Without antibiotics, AOM resolves within 24 hours in about 60% of children, and within 3 days in about 80% of children.

  Analgesics and topical anaesthetics may reduce earache.
Antibiotics seem to reduce pain at 2 to 7 days, but they increase the risks of vomiting, diarrhoea, and rashes compared with placebo.

Immediate antibiotic use seems most beneficial in children aged <2 years with bilateral AOM and in children with AOM presenting with otorrhoea.

We do not know whether any one antibiotic regimen should be used in preference to another, although amoxicillin may be more effective than macrolides, and it should be considered as first-line treatment.

Longer courses of antibiotics reduce short-term treatment failure but have no benefit in the longer term compared with shorter regimens.

Immediate use of antibiotics may provide short-term reduction in some symptoms of AOM, but it increases the risk of diarrhoea and rashes compared with delayed treatment.

- Myringotomy seems less effective than antibiotics at reducing symptoms.
- We found limited evidence of only a short-term benefit from tympanostomy with ventilation tubes, with possibly increased risks of tympanosclerosis.
- Long-term antibiotic prophylaxis may reduce recurrence rates; however, the possibility of adverse effects and antibiotic resistance should be taken into account.

We do not know whether any one regimen should be used in preference to another to prevent recurrent attacks.

- Vaccination in infancy with pneumococcal conjugate vaccine (PCV) has some effect on recurrent AOM.
- Influenza vaccine in healthy children has no effect on incidence of AOM.
- Xylitol given 5 times daily as prophylaxis has a small preventive effect on recurrent AOM, but the compliance issues in giving a medicine 5 times daily to such young children render it an unrealistic treatment option.

**DEFINITION**

Otitis media is an inflammation in the middle ear. Subcategories include acute otitis media (AOM), recurrent AOM, and chronic suppurative otitis media (CSOM). AOM is the presence of middle-ear effusion in conjunction with rapid onset of one or more signs or symptoms of inflammation of the middle ear. AOM presents with systemic and local signs, and it has a rapid onset. The diagnosis is made on the basis of signs and symptoms, principally earache in the presence of a cloudy or bulging eardrum (and immobility of the eardrum if pneumatic otoscopy is performed). Erythema is a moderately useful sign for helping to establish the diagnosis. If the eardrum has a normal colour, then risk of AOM is low. Uncomplicated AOM is limited to the middle-ear cleft. The persistence of an effusion beyond 3 months without signs of infection defines otitis media with effusion (also known as ‘glue ear’; see review on otitis media with effusion), which can arise as a consequence of AOM, but can also occur independently. CSOM is characterised by continuing inflammation in the middle ear causing discharge (otorrhoea) through a perforated tympanic membrane (see review on CSOM). This review deals only with AOM in children.

**INCIDENCE/PREVALENCE**

AOM is common, and has a high morbidity and low mortality in otherwise healthy children. In the UK, about 30% of children under 3 years visit their general practitioner with AOM each year, and 97% receive antimicrobial treatment. By 3 months of age, 10% of children have had an episode of AOM. It is the most common reason for outpatient antimicrobial treatment in the US.

**AETIOLOGY/RISK FACTORS**

The most common bacterial causes of AOM in the US and UK are *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*. Similar pathogens are found in Colombia. There is some evidence that the predominant causative pathogen in recurrent AOM is changing from *Streptococcus pneumoniae* to *Haemophilus influenzae* after the release and widespread use of pneumococcal conjugate vaccine. The established modifiable risk factors for recurrent AOM are the use of pacifiers, and care in daycare centres. Probable risk factors are privation of mother’s milk, presence of siblings, craniofacial abnormalities, passive smoking, and presence of adenoids.

**PROGNOSIS**

Without antibiotic treatment, AOM symptoms improve in 24 hours in about 60% of children, and in about 80% of children the condition resolves in about 3 days. Suppurative complications occur in about 0.12% of children if antibiotics are withheld. Serious complications are rare in otherwise healthy children but include hearing loss, mastoiditis, meningitis, and recurrent attacks. The WHO estimates that, in developing countries, 51,000 children aged <5 years die from complications of otitis media each year.

**AIMS OF INTERVENTION**

To reduce the severity and duration of pain and other symptoms; to prevent complications; to minimise adverse effects of treatment.
OUTCOMES Symptoms of AOM (including pain [which can be assessed by surrogate measures such as parental observation of distress/crying and analgesic use], fever, middle-ear effusion, and otoscopic appearance); recurrence of infection, mastoiditis, and meningitis; complications of infection (including deafness), adverse effects of treatment.

METHODS Clinical Evidence search and appraisal September 2010. The following databases were used to identify studies for this systematic review: Medline 1966 to September 2010, Embase 1980 to September 2010, and The Cochrane Database of Systematic Reviews, August 2010 (online; 1966 to date of issue). This review was edited using The Cochrane Database of Systematic Reviews 2010, Issue 4. An additional search within The Cochrane Library was carried out for the Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA). We also searched for retractions of studies included in the review. Abstracts of the studies retrieved from the initial search were assessed by an information specialist. Selected studies were then sent to the contributor for additional assessment, using predetermined criteria to identify relevant studies. Study design criteria for inclusion in this review were: published systematic reviews of RCTs and RCTs in any language, at least single blinded, and containing >20 individuals of whom >80% were followed up. There was no minimum length of follow-up required to include studies. We excluded all studies described as “open”, “open label”, or not blinded unless blinding was impossible. We included systematic reviews of RCTs and RCTs where harms of an included intervention were studied applying the same study design criteria for inclusion as we did for benefits. In addition we use a regular surveillance protocol to capture harms alerts from organisations such as the FDA and the MHRA, which are added to the reviews as required. To aid readability of the numerical data in our reviews, we round many percentages to the nearest whole number. Readers should be aware of this when relating percentages to summary statistics such as relative risks (RRs) and odds ratios (ORs). We have performed a GRADE evaluation of the quality of evidence for interventions included in this review (see table, p 29 ). The categorisation of the quality of the evidence (high, moderate, low, or very low) reflects the quality of evidence available for our chosen outcomes in our defined populations of interest. These categorisations are not necessarily a reflection of the overall methodological quality of any individual study, because the Clinical Evidence population and outcome of choice may represent only a small subset of the total outcomes reported, and population included, in any individual trial. For further details of how we perform the GRADE evaluation and the scoring system we use, please see our website (www.clinicalevidence.com).

QUESTION What are the effects of treatments for AOM in children?

OPTION ANALGESICS

- For GRADE evaluation of interventions for AOM in children, see table, p 29.
- Analgesics and topical anaesthetics may reduce earache compared with placebo.
- Note: A drug safety alert has been issued by the Food Drug Administration (FDA) on the risk of rare but serious skin reactions with paracetamol (acetaminophen).

Benefits and harms

Topical anaesthetic versus placebo:
We found one systematic review (search date 2009, 2 RCTs). [10]

Symptoms of AOM
Compared with placebo Topical anaesthetic drops may be more effective at reducing earache 10 to 30 minutes after administration in children taking paracetamol (low-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[10] Systematic review</td>
<td>117 people aged 3 to 19 years 2 RCTs in this analysis</td>
<td>25% reduction in ear ache, 10 minutes 37/58 (64%) with topical anaesthetic drops 25/59 (42%) with placebo</td>
<td>RR 1.51 95% CI 1.06 to 2.15 P = 0.02 NNT 4 95% CI 3 to 27</td>
<td>○ ○</td>
<td>topical anaesthetic drops</td>
</tr>
</tbody>
</table>
### AOM in children

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
</table>
| Systematic review | 117 people aged 3 to 19 years | 25% reduction in ear ache, 20 minutes | RR 1.34  
95% CI 1.04 to 1.71  
P = 0.02  
NNT 5  
95% CI 3 to 27 | ☀️☀️☀️ | topical anaesthetic drops |
| | 2 RCTs in this analysis | 46/58 (79%) with topical anaesthetic drops  
35/59 (59%) with placebo | All participants also received paracetamol. See further information on studies for full details of co-interventions |
| | | | |
| Systematic review | 117 people aged 3 to 19 years | 25% reduction in ear ache, 30 minutes | RR 1.34  
95% CI 1.12 to 1.61  
P = 0.002  
NNT 5  
95% CI 3 to 10 | ☀️☀️☀️ | topical anaesthetic drops |
| | 2 RCTs in this analysis | 54/58 (93%) with topical anaesthetic drops  
41/59 (69%) with placebo | All participants also received paracetamol. See further information on studies for full details of co-interventions |
| | | | |
| Systematic review | 117 people aged 3 to 19 years | 50% reduction in ear ache, 10 minutes | RR 2.13  
95% CI 1.19 to 3.80  
P = 0.01  
NNT 4  
95% CI 3 to 16 | ☀️☀️☀️ | topical anaesthetic drops |
| | 2 RCTs in this analysis | 25/58 (43%) with topical anaesthetic drops  
12/59 (20%) with placebo | All participants also received paracetamol. See further information on studies for full details of co-interventions |
| | | | |
| Systematic review | 117 people aged 3 to 19 years | 50% reduction in ear ache, 20 minutes | RR 1.24  
95% CI 0.88 to 1.74  
P = 0.22 | | Not significant |
| | 2 RCTs in this analysis | 34/58 (59%) with topical anaesthetic drops  
28/59 (47%) with placebo | All participants also received paracetamol. See further information on studies for full details of co-interventions |
| | | | |
| Systematic review | 117 people aged 3 to 19 years | 50% reduction in ear ache, 30 minutes | RR 1.43  
95% CI 1.12 to 1.81  
P = 0.003  
NNT 4  
95% CI 3 to 11 | ☀️☀️ | topical anaesthetic drops |
| | 2 RCTs in this analysis | 49/58 (84%) with topical anaesthetic drops  
35/59 (59%) with placebo | All participants also received paracetamol. See further information on studies for full details of co-interventions |

### Recurrence

No data from the following reference on this outcome.  

---

© BMJ Publishing Group Ltd 2011. All rights reserved.
Complications

No data from the following reference on this outcome. [10]

Adverse effects

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[10]</td>
<td>63 people aged 3 to 19 years Data from 1 RCT</td>
<td>Adverse effects with topical anaesthetic drops with placebo</td>
<td>One RCT in the review reported on adverse effects. The review reported that 3 people (treatment arm not specified) had mild dizziness that required no further treatment. All participants also received paracetamol. See further information on studies for full details of co-interventions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Oral analgesics versus placebo:
We found one RCT comparing the effects of treatment with ibuprofen or paracetamol three times daily versus placebo for 48 hours. [11]

Symptoms of AOM

Compared with placebo Oral ibuprofen or paracetamol may be more effective at reducing pain after 48 hours in children taking antibiotics (low-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[11]</td>
<td>219 children, aged 1 to 6 years with otoscopically diagnosed AOM and receiving antibiotic treatment with cefaclor for 7 days</td>
<td>Incidence of ear ache, 2 days 5/71 (7%) with ibuprofen 19/75 (25%) with placebo Parent assessed outcome</td>
<td>P &lt;0.01</td>
<td></td>
<td>ibuprofen</td>
</tr>
<tr>
<td>[11]</td>
<td>219 children, aged 1 to 6 years with otoscopically diagnosed AOM and receiving antibiotic treatment with cefaclor for 7 days</td>
<td>Incidence of ear ache, 2 days 7/73 (10%) with paracetamol 19/75 (25%) with placebo Parent assessed outcome</td>
<td>P value not reported Reported as non-significant</td>
<td></td>
<td>Not significant</td>
</tr>
</tbody>
</table>

Recurrence

No data from the following reference on this outcome. [11]

Complications

© BMJ Publishing Group Ltd 2011. All rights reserved.
No data from the following reference on this outcome. [11]

Adverse effects

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCT</td>
<td>219 children, aged 1 to 6 years with otoscopy diagnosed AOM and receiving antibiotic treatment with cefaclor for 7 days</td>
<td>Adverse effects (including mild nausea, vomiting, or abdominal pain) 5/71 (7%) with ibuprofen 3/75 (4%) with placebo</td>
<td>Significance not assessed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT</td>
<td>219 children, aged 1 to 6 years with otoscopy diagnosed AOM and receiving antibiotic treatment with cefaclor for 7 days</td>
<td>Adverse effects (including mild nausea, vomiting, or abdominal pain) 3/73 (4.1%) with paracetamol 3/75 (4.0%) with placebo</td>
<td>Significance not assessed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Further information on studies

[11] The evidence from this RCT is limited because the assessment of the child's pain relief was based on parental observation using a scale of 0 or 1.

[10] The review included studies in which participants were also given oral analgesics. It is therefore difficult to properly assess the real effects of the anaesthetic ear drops.

Comment: None.

OPTION ANTIBIOTICS VERSUS PLACEBO

- For GRADE evaluation of interventions for AOM in children, see table, p 29.
- Antibiotics may lead to more rapid reduction in symptoms of AOM, but they increase the risk of adverse effects.
- Antibiotics seem to reduce pain at 2 to 7 days, but they increase the risks of vomiting, diarrhoea, and rashes compared with placebo.
- Antibiotics seem most effective in children aged <2 years with bilateral AOM and in children with AOM presenting with otorrhoea.

Benefits and harms

Antibiotics versus placebo:
We found 4 systematic reviews (search dates 1997,[12] 2008,[13] and 2005[14][15]).

Symptoms of AOM
Compared with placebo Antibiotics may be more effective at reducing pain and other symptoms of AOM after 2 to 14 days (low-quality evidence).
## Symptoms of AOM

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[12] Systematic review</td>
<td>741 children aged &lt;2 years</td>
<td>Symptomatic improvement, 7 days</td>
<td>OR 1.31 (weighted OR, Mantel–Haenszel) 95% CI 0.83 to 2.08</td>
<td>←</td>
<td>Not significant</td>
</tr>
<tr>
<td></td>
<td>4 RCTs in this analysis</td>
<td>Antibiotic treatment included penicillins, sulphonamide, amoxicillin–clavulanic acid (co-amoxiclav)</td>
<td>See further information on studies for definitions of AOM in trials</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pain, fever, or both, 3 to 7 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[13] Systematic review</td>
<td>2791 children aged 6 months to 15 years</td>
<td>Pain, 2 to 7 days</td>
<td>ARR 6% 95% CI 4% to 9% RR 0.72 95% CI 0.19 to 0.40 P &lt;0.001 NNT 16 95% CI 11 to 25</td>
<td>antibiotics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9 RCTs in this analysis</td>
<td>228/1425 (16%) with erythromycin, penicillins, sulphonamides 303/1366 (22%) with placebo</td>
<td>Pain was assessed using parental report/score card/diary or clinician assessment at 4 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pain outcomes, 24 hours</td>
<td>RR 0.90 95% CI 0.78 to 1.04</td>
<td>←</td>
<td>Not significant</td>
</tr>
<tr>
<td></td>
<td>223/624 (36%) with antibiotics 241/605 (40%) with placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[15] Systematic review</td>
<td>273 children &lt;2 years with bilateral AOM</td>
<td>Pain, fever, or both, 3 to 7 days</td>
<td>RR 0.64 95% CI 0.62 to 0.80 The differences for children aged &lt;2 years with unilateral AOM and in children &gt;2 years with unilateral or bilateral AOM were not significant</td>
<td>antibiotics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 RCTs in this analysis</td>
<td>42/140 (30%) with antibiotics 74/133 (55%) with placebo</td>
<td>Pain was assessed using parental report/score card/diary or clinician assessment at 4 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Subgroup analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[15] Systematic review</td>
<td>116 children aged 6 months to 12 years presenting with otitis media</td>
<td>Pain, fever, or both, 3 to 7 days</td>
<td>RR 0.52 95% CI 0.37 to 0.73 P = 0.04</td>
<td>antibiotics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 RCTs in this analysis</td>
<td>12/50 (24%) with antibiotics 39/66 (60%) with placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Subgroup analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

No data from the following reference on this outcome. [14]

### Recurrence

**Compared with placebo** Antibiotics are no more effective at reducing the rate of recurrence in children with AOM (high-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[13] Systematic review</td>
<td>2153 people aged 6 months to 15 years</td>
<td>Recurrence</td>
<td>RR 0.93 95% CI 0.79 to 1.10</td>
<td>←</td>
<td>Not significant</td>
</tr>
<tr>
<td></td>
<td>6 RCTs in this analysis</td>
<td>Recurrence 214/1113 (19%) with penicillins 214/1040 (21%) with placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© BMJ Publishing Group Ltd 2011. All rights reserved.
Complications

**Compared with placebo** Antibiotics seem no more effective at reducing the risk of abnormal tympanometry at 1 and 3 months in children with AOM (moderate-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal tympanometry</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[13] Systematic review</td>
<td>808 children aged 6 months to 10 years</td>
<td>Abnormal tympanometry, 3 months&lt;br&gt;96/410 (23%) with antibiotics&lt;br&gt;96/460 (24%) with placebo</td>
<td>RR 0.97&lt;br&gt;95% CI 0.76 to 1.24&lt;br&gt;P = 0.81</td>
<td>↔</td>
<td>Not significant</td>
</tr>
<tr>
<td>[13] Systematic review</td>
<td>927 children aged 6 months to 12 years</td>
<td>Abnormal tympanometry, 1 month&lt;br&gt;153/467 (33%) with antibiotics&lt;br&gt;168/460 (37%) with placebo</td>
<td>RR 0.89&lt;br&gt;95% CI 0.75 to 1.07&lt;br&gt;P = 0.21</td>
<td>↔</td>
<td>Not significant</td>
</tr>
<tr>
<td>[14] Systematic review</td>
<td>1328 children aged 6 months to 12 years</td>
<td>Abnormal tympanometry, 1 month&lt;br&gt;47% with antibiotics&lt;br&gt;51% with placebo or no treatment&lt;br&gt;Absolute numbers not reported</td>
<td>RR 0.93&lt;br&gt;95% CI 0.82 to 1.04</td>
<td>↔</td>
<td>Not significant</td>
</tr>
</tbody>
</table>

No data from the following reference on this outcome. [12] [14] [15]

Adverse effects

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[13] Systematic review</td>
<td>1401 children, aged 6 months to 15 years</td>
<td>Adverse effects, including vomiting, diarrhoea, or rashes&lt;br&gt;110/690 (16%) with antibiotics&lt;br&gt;83/711 (11%) with placebo</td>
<td>RR 1.38&lt;br&gt;95% CI 1.09 to 1.76&lt;br&gt;P = 0.008&lt;br&gt;NNH 24&lt;br&gt;95% CI 9 to 152</td>
<td>⬠ ⬠</td>
<td>placebo</td>
</tr>
</tbody>
</table>

No data from the following reference on this outcome. [12] [14] [15]

Further information on studies

[12] Three RCTs based diagnosis of AOM on otoscopic appearance of the tympanic membrane and clinical signs of acute infection, and one RCT based diagnosis on otoscopy findings alone.
Clinical guide:
The results of systematic reviews comparing antibiotics versus placebo may vary owing to differences in entry criteria and outcome measures. One quasi-randomised trial from Sweden conducted in 1954 comparing the effects of antibiotics versus placebo found no cases of mastoiditis in the penicillin-treated group, whereas 17% of the control group developed mastoiditis. Therefore, in populations in which the incidence of complicating mastoiditis is high, antibiotic treatment would be advised.

**OPTION**

**CHOICE OF ANTIBIOTIC REGIMEN**

- For GRADE evaluation of interventions for AOM in children, see table, p 29.
- We do not know whether any one antibiotic regimen should be used in preference to another, but amoxicillin may be more effective than macrolides, and it should be considered as first-line treatment.
- **Note**
  Antibiotics increase the risk of vomiting, diarrhoea, and rashes compared with placebo, but rates may vary between different types of antibiotic.

**Benefits and harms**

**Different antibiotics versus each other:**

We found three systematic reviews (search dates 1992, 1999, and 2008).

**Symptoms of AOM**

**Different antibiotics compared with each other** Macrolide antibiotics may be less effective than amoxicillin or amoxicillin–clavulanic acid (co-amoxiclav) at reducing signs and symptoms of AOM after 7 to 14 days, while other antibiotics may be as effective as each other (very low-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptoms of AOM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[17] Systematic review</td>
<td>4580 children aged 4 months to 18 years, 27 RCTs in this analysis</td>
<td>Primary control defined as absence of any symptom or sign, 7 to 14 days with with Absolute numbers not reported The review reported comparisons of a range of antibiotics, including ampicillin, amoxicillin, cefaclor, cefixime, amoxicillin–clavulanic acid (co-amoxiclav), erythromycin, penicillin, and sulfafurazole</td>
<td>P values not reported Reported as not significant for all comparisons</td>
<td>↔</td>
<td>Not significant</td>
</tr>
<tr>
<td>[2] Systematic review</td>
<td>491 children, aged 4 weeks to 18 years, 3 RCTs in this analysis</td>
<td>Clinical failure rate, 7 to 14 days with penicillin with ampicillin or amoxicillin Absolute results not reported</td>
<td>Clinical failure rate difference: +4.5% 95% CI –1.8% to +10.7%</td>
<td>↔</td>
<td>Not significant</td>
</tr>
<tr>
<td>[2] Systematic review</td>
<td>185 children, aged 4 weeks to 18 years, 4 RCTs in this analysis</td>
<td>Clinical failure rates, 3 to 7 days with cefaclor with ampicillin or amoxicillin Absolute numbers not reported</td>
<td>Clinical failure rate difference –5.4% 95% CI –15.2% to +4.4%</td>
<td>↔</td>
<td>Not significant</td>
</tr>
<tr>
<td>[18] Systematic review</td>
<td>2766 children aged 6 months to 15 years, 10 RCTs in this analysis</td>
<td>Clinical failure, 10 to 16 days 146/1371 (11%) with amoxicillin or amoxicillin–clavulanic acid 196/1395 (14%) with macrolide antibiotics</td>
<td>RR 1.31 95% CI 1.07 to 1.60 P = 0.008</td>
<td>○ ○</td>
<td>amoxicillin or amoxicillin–clavulanic acid</td>
</tr>
</tbody>
</table>
Recurrence

No data from the following reference on this outcome. [2] [17] [18]

Complications

No data from the following reference on this outcome. [2] [17] [18]

Adverse effects

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Diarrhoea</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[2] Systematic review</td>
<td>1518 patients aged 4 weeks to 18 years 5 RCTs in this analysis</td>
<td>with cefixime with amoxicillin or ampicillin Absolute numbers not reported</td>
<td>ARI 8.4% 95% CI 3.8% to 13.1% NNH 12 95% CI 8 to 27</td>
<td>☐ ☐ ☐</td>
<td>amoxicillin or ampicillin</td>
</tr>
<tr>
<td>[2] Systematic review</td>
<td>1366 patients aged 4 weeks to 18 years 3 RCTs in this analysis</td>
<td>Gastrointestinal adverse effects with amoxicillin–clavulanic acid (co-amoxiclav) with azithromycin Absolute numbers not reported</td>
<td>ARI 18% 95% CI 8% to 28% NNH 6 95% CI 4 to 13</td>
<td>☐ ☐ ☐</td>
<td>azithromycin</td>
</tr>
<tr>
<td>[18] Systematic review</td>
<td>2766 children aged 6 months to 15 years 10 RCTs in this analysis</td>
<td>Adverse effects with amoxicillin or amoxicillin–clavulanic acid with macrolide antibiotics Absolute numbers not reported</td>
<td>RR 0.74 95% CI 0.60 to 0.90 P = 0.003</td>
<td>☐ ☐</td>
<td>macrolide antibiotics</td>
</tr>
</tbody>
</table>

No data from the following reference on this outcome. [17]

Further information on studies

[2] Clinical failure was defined as the presence of pain, fever, middle-ear effusion, clinical signs of otitis media, or suppurative complications such as mastoiditis.

[17] AOM was defined as bulging or opacification of the tympanic membrane with or without erythema, accompanied by at least one sign (fever, ear ache, irritability, otorrhoea, lethargy, anorexia, vomiting, diarrhoea, poor or absent mobility of the tympanic membrane). Treatment success was defined as absence of all presenting signs and symptoms of AOM at the evaluation point closest to 7 to 14 days after start of treatment.

Comment: Clinical guide:
Many RCTs have studied a variety of antibiotic regimens for the treatment of otitis media, but there is heterogeneity in participants, treatment regimens, controls, and outcome measures.
For GRADE evaluation of interventions for AOM in children, see table, p 29.

Immediate use of antibiotics may provide short-term reduction for some symptoms of AOM, but it increases the risk of rashes and diarrhoea compared with delayed treatment.

**Benefits and harms**

**Immediate versus delayed antibiotic treatment:**

We found one systematic review (search date 2009).\(^{19}\) Owing to heterogeneity among studies, the review did not perform meta-analyses, so we report data from individual RCTs here.

**Symptoms of AOM**

Immediate antibiotics compared with delayed antibiotics Immediate antibiotics may be more effective at reducing pain and other symptoms of AOM at 3 days, but not after 7 days (moderate-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Proportion of children with pain, 3 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[19] Systematic review</td>
<td>212 children aged 6 months to 10 years Data from 1 RCT</td>
<td>28/111 (25%) with delayed antibiotics 15/101 (15%) with immediate antibiotics</td>
<td>OR 1.93 95% CI 0.96 to 3.88</td>
<td>←→</td>
<td>Not significant</td>
</tr>
<tr>
<td>[19] Systematic review</td>
<td>212 children aged 6 months to 10 years Data from 1 RCT</td>
<td>3/111 (3%) with delayed antibiotics 0/101 (0%) with immediate antibiotics</td>
<td>OR 6.55 95% CI 0.33 to 128.34</td>
<td>←→</td>
<td>Not significant</td>
</tr>
<tr>
<td>[19] Systematic review</td>
<td>285 children aged 6 months to 10 years Data from 1 RCT</td>
<td>45/150 (30%) with delayed antibiotics 19/135 (14%) with immediate antibiotics</td>
<td>OR 2.62 95% CI 1.44 to 4.76</td>
<td>✅✅</td>
<td>Immediate antibiotics</td>
</tr>
<tr>
<td>[19] Systematic review</td>
<td>213 children aged 6 months to 10 years Data from 1 RCT</td>
<td>2.56 with delayed antibiotics 1.81 with immediate antibiotics</td>
<td>Mean difference 0.75 95% CI 0.26 to 1.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[19] Systematic review</td>
<td>212 children aged 6 months to 10 years Data from 1 RCT</td>
<td>1.17 with delayed antibiotics 1.05 with immediate antibiotics</td>
<td>Mean difference +0.12 95% CI 0.04 to +0.28</td>
<td>←→</td>
<td>Not significant</td>
</tr>
<tr>
<td>[19] Systematic review</td>
<td>282 children aged 6 months to 12 years Data from 1 RCT</td>
<td>2.28 with delayed antibiotics 1.69 with immediate antibiotics</td>
<td>Mean difference 0.59 95% CI 0.25 to 0.93</td>
<td>✅✅</td>
<td>Immediate antibiotics</td>
</tr>
<tr>
<td>[19] Systematic review</td>
<td>265 children aged 6 months to 12 years Data from 1 RCT</td>
<td>42/132 (32%) with delayed antibiotics 46/133 (35%) with immediate antibiotics</td>
<td>OR 0.88 95% CI 0.53 to 1.47</td>
<td>←→</td>
<td>Not significant</td>
</tr>
</tbody>
</table>
Recurrence

No data from the following reference on this outcome. [19]

Complications

No data from the following reference on this outcome. [19]

Adverse effects

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[19]</td>
<td>Systematic review</td>
<td>285 children aged between 6 months and 12 years</td>
<td>Rash  8/150 (5%) with delayed antibiotics  14/150 (9%) with immediate antibiotics</td>
<td>OR 1.21  95% CI 0.41 to 2.58</td>
<td>←→  Not significant</td>
</tr>
<tr>
<td>[19]</td>
<td>Systematic review</td>
<td>265 children aged between 6 months and 12 years</td>
<td>Diarrhoea  10/132 (8%) with delayed antibiotics  31/133 (23%) with immediate antibiotics</td>
<td>OR 0.27  95% CI 0.13 to 0.58</td>
<td>● ● ○  delayed antibiotics</td>
</tr>
<tr>
<td>[19]</td>
<td>Systematic review</td>
<td>265 children aged between 6 months and 12 years</td>
<td>Vomiting  15/132 (11.4%) with delayed antibiotics  15/133 (11.3%) with immediate antibiotics</td>
<td>OR 1.01  95% CI 0.47 to 2.16</td>
<td>←→  Not significant</td>
</tr>
</tbody>
</table>
Further information on studies

Comment: Prescribing delayed antibiotics, using a prescription to be filled later if symptoms do not improve, is a tool for the physician to reduce antibiotic use rather than a treatment option for AOM. If antibiotics have a small effect on the outcome of AOM, then this effect will clearly apply to immediate antibiotics. Because the evidence suggests that antibiotics should only be prescribed to certain subgroups of patients (children aged <2 years with bilateral AOM and children with AOM presenting with otorrhea), physicians should discuss the wait-and-see policy with parents of children not in those subgroups. A delayed prescription should be provided with care, since oral antibiotics may not always be the best option in very young children with worsening symptoms. In these cases the physician and not the parents of the child should make the decision about whether to give antibiotics. In most developed countries, it is relatively easy for parents to re-consult a physician when symptoms either do not improve or get worse.

One study in the review showed no difference in re-consultation rate between the two groups. One study comparing delayed antibiotics versus no antibiotics showed no difference in the outcomes of pain and fever.

OPTION LONGER VERSUS SHORTER COURSES OF ANTIBIOTICS

- For GRADE evaluation of interventions for AOM in children, see table, p 29.
- Longer courses of antibiotics reduce short-term treatment failure, but have no benefit over the longer term compared with shorter regimens.

Benefits and harms

Longer versus shorter course of antibiotics: We found one systematic review (search date 2009).

Symptoms of AOM

Longer courses of antibiotics compared with shorter courses Longer (8–10 days) courses of antibiotics are more effective at reducing symptoms and preventing relapse or re-infection at 8 to 19 days compared with 7-day courses, but are no more effective than shorter courses after 20 to 30 days (high-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic review</td>
<td>5093 children aged between 4 weeks and 15 years, 16 RCTs in this analysis</td>
<td>Treatment failure, 1 month or less 486/2376 (20%) with short-course antibiotics (&lt;7 days) 475/2717 (17%) with longer-course antibiotics (8–10 days) See further information on studies for definition of treatment failure</td>
<td>OR 1.34 95% CI 1.15 to 1.55 P = 0.0001</td>
<td>[○ ○ ○] longer-course antibiotics</td>
<td></td>
</tr>
<tr>
<td>Systematic review</td>
<td>3932 children aged between 4 weeks and 15 years, 11 RCTs in this analysis</td>
<td>Treatment failure, 8 to 19 days 340/1892 (18%) with short-course antibiotics (&lt;7 days) 283/2040 (14%) with longer-course antibiotics (8–10 days) See further information on studies for definition of treatment failure</td>
<td>OR 1.37 95% CI 1.15 to 1.64 P = 0.0004</td>
<td>[○ ○ ○] longer-course antibiotics</td>
<td></td>
</tr>
<tr>
<td>Ref (type)</td>
<td>Population</td>
<td>Outcome, Interventions</td>
<td>Results and statistical analysis</td>
<td>Effect size</td>
<td>Favours</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>------------------------</td>
<td>---------------------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>[21] Systematic review 2475 children aged between 4 weeks and 15 years 9 RCTs in this analysis</td>
<td>Treatment failure, 20 to 30 days 238/1141 (21%) with short-course antibiotics (&lt;7 days) 271/1335 (20%) with longer-course antibiotics (8–10 days) See further information on studies for definition of treatment failure</td>
<td>OR 1.16 95% CI 0.94 to 1.42</td>
<td></td>
<td>←→</td>
<td>Not significant</td>
</tr>
<tr>
<td>[21] Systematic review 2068 children aged between 4 weeks and 15 years 7 RCTs in this analysis</td>
<td>Treatment failure, 3 months or less 391/973 (40%) with short-course antibiotics (&lt;7 days) 399/1095 (36%) with longer-course antibiotics (8–10 days) See further information on studies for definition of treatment failure</td>
<td>OR 1.18 95% CI 0.98 to 1.41</td>
<td></td>
<td>←→</td>
<td>Not significant</td>
</tr>
<tr>
<td>[21] Systematic review 570 children aged between 4 weeks and 2 years 5 RCTs in this analysis</td>
<td>Treatment failure, 1 month or less 99/296 (33%) with short-course antibiotics (&lt;7 days) 85/274 (31%) with longer-course antibiotics (8–10 days) See further information on studies for definition of treatment failure</td>
<td>OR 1.09 95% CI 0.76 to 1.57</td>
<td></td>
<td>←→</td>
<td>Not significant</td>
</tr>
<tr>
<td>[21] Systematic review 1064 children aged between 2 years and 15 years 6 RCTs in this analysis</td>
<td>Treatment failure, 1 month or less 74/530 (14%) with short-course antibiotics (&lt;7 days) 86/534 (16%) with longer-course antibiotics (8–10 days) See further information on studies for definition of treatment failure</td>
<td>OR 0.85 95% CI 0.60 to 1.21</td>
<td></td>
<td>←→</td>
<td>Not significant</td>
</tr>
</tbody>
</table>

**Recurrence**

No data from the following reference on this outcome. [21]

**Complications**

No data from the following reference on this outcome. [21]

**Adverse effects**

© BMJ Publishing Group Ltd 2011. All rights reserved.
### Gastrointestinal adverse effects

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[21] Systematic review</td>
<td>4918 children aged between 4 weeks years and 15 years 13 RCTs in this analysis</td>
<td>Gastrointestinal adverse effects 206/2221 (9%) with short-course antibiotics (&lt;7 days) 369/2697 (14%) with longer-course antibiotics (8–18 days)</td>
<td>OR 0.72 95% CI 0.60 to 0.87</td>
<td>short-course antibiotics (&lt;7 days)</td>
<td>○○ ○</td>
</tr>
</tbody>
</table>

### Further information on studies

[21] Treatment failure was defined as lack of clinical resolution, relapse, or recurrence of AOM during a 1-month period following the initiation of therapy. Clinical resolution was defined as improved or resolving signs or symptoms of AOM. Treatment failure at 3 months was defined as relapses and recurrences up to 3 months.

### Comment

A subgroup analysis showed that children aged <2 years had no benefit from longer courses of antibiotics compared with shorter courses. In addition, they had a greater risk of treatment failure compared with older children irrespective of treatment duration. [21]

### OPTION MYRINGOTOMY

- For GRADE evaluation of interventions for AOM in children, see table, p 29.
- Myringotomy seems less effective than antibiotics at reducing symptoms.
- **Adverse effects**
  - Myringotomy may be less likely than antibiotics to cause diarrhoea.

### Benefits and harms

**Myringotomy versus no myringotomy:**

We found one RCT. [22]

### Symptoms of AOM

**Compared with no myringotomy** Myringotomy may be no more effective than no myringotomy at reducing the symptoms of AOM after 1 to 7 days (low-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[24] RCT 4-armed trial</td>
<td>171 children, aged 2 to 12 years with AOM The third arm evaluated amoxicillin (250 mg three times daily for 7 days) only The fourth arm evaluated amoxicillin plus myringotomy</td>
<td>Pain, 24 hours 26/36 (72.2%) with myringotomy only 29/40 (72.5%) with no treatment</td>
<td>P value not reported Reported as not significant for myringotomy v no treatment</td>
<td>[ ] Not significant</td>
<td></td>
</tr>
</tbody>
</table>
Favours

Effect

size

Results and statistical

analysis

Outcome, Interventions

Population

Ref (type)

[22] RCT

4-armed trial

171 children, aged 2 to 12 years with AOM
The third arm evaluated amoxicillin (250 mg three times daily for 7 days) only
The fourth arm evaluated amoxicillin plus myringotomy
Pain, 7 days
31/35 (89%) with myringotomy only
34/38 (90%) with no treatment
P value not reported
Reported as not significant for myringotomy vs no treatment
Not significant

Recurrence

No data from the following reference on this outcome. [22]

Complications

No data from the following reference on this outcome. [22]

Adverse effects

No data from the following reference on this outcome. [22]

Myringotomy versus antibiotics:
We found no systematic review but found three RCTs. [23] [22] [24]

Symptoms of AOM

Compared with antibiotics Myringotomy may be less effective at reducing symptoms of AOM after 12 hours to 11 days (low-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCT 3-armed trial</td>
<td>105 infants aged 3 months to 1 year with AOM</td>
<td>Persistent ear infection, 9 to 11 days</td>
<td>P &lt;0.001</td>
<td></td>
<td>antibiotic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21/30 (70%) with myringotomy plus placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2/30 (7%) with antibiotic (amoxicillin–clavulanic acid)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>60 children in this analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT 3-armed trial</td>
<td>105 infants aged 3 months to 1 year with AOM</td>
<td>Persistent ear infection, 3 to 6 days</td>
<td>P &lt;0.0001</td>
<td></td>
<td>antibiotic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>28/35 (80%) with myringotomy plus placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Results and statistical analysis

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[22] RCT 4-armed trial</td>
<td>171 children aged 2 to 12 years with AOM</td>
<td>No pain, 24 hours</td>
<td>P value not reported</td>
<td>←</td>
<td>Not significant</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reported as not significant for myringotomy vs amoxicillin alone</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The remaining arms evaluated amoxicillin plus myringotomy and no treatment</td>
<td>26/36 (72.2%) with myringotomy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>34/47 (72.3%) with amoxicillin (250 mg three times daily for 7 days)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>83 children in this analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[22] RCT 4-armed trial</td>
<td>171 children aged 2 to 12 years with AOM</td>
<td>No pain, 7 days</td>
<td>P value not reported</td>
<td>←</td>
<td>Not significant</td>
</tr>
<tr>
<td></td>
<td>The remaining arms evaluated amoxicillin plus myringotomy and no treatment</td>
<td>31/35 (89%) with myringotomy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>43/46 (93%) with amoxicillin (250 mg three times daily for 7 days)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>81 children in this analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[24] RCT 3-armed trial</td>
<td>83 episodes of AOM in children, aged 2 to 12 years with severe AOM or recurrent AOM</td>
<td>Initial treatment failure, 12 hours</td>
<td>P = 0.006</td>
<td>⚫ ⬤</td>
<td>amoxicillin</td>
</tr>
<tr>
<td></td>
<td>The remaining arm evaluated myringotomy plus amoxicillin</td>
<td>23% with myringotomy plus placebo</td>
<td>Results include severe episodes of AOM in children aged 2 to 12 years only</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4% with amoxicillin (40 mg/kg/day in 3 divided doses for 14 days)</td>
<td>Absolute numbers not reported</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Recurrence

No data from the following reference on this outcome. [23] [22] [24]

### Complications

No data from the following reference on this outcome. [23] [22] [24]

### Adverse effects

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[23] RCT 3-armed trial</td>
<td>105 infants, aged 3 months to 1 year with AOM</td>
<td>Loose or watery bowel movements</td>
<td>P = 0.05</td>
<td>⬤ ⬤</td>
<td>myringotomy plus placebo</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0/30 (0%) with myringotomy plus placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7/60 (12%) with antibiotic (amoxicillin–clavulanic acid)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

No data from the following reference on this outcome. [22] [24]
Further information on studies

[22] The RCT provided results in the form of children or as individual ears as the unit measured. Because randomisation was based on children, the figures reported here exclude those results based on individual ears.

[23] AOM was defined as the presence of middle-ear effusion and bulging (with or without redness of the tympanic membrane) associated with recent irritability or fever. The RCT provided results in the form of children or as individual ears as the unit measured. Because randomisation was based on children, the figures reported here exclude those results based on individual ears.

[24] AOM was diagnosed on the basis of fever, ear ache, or irritability with redness and/or bulging of the eardrum. An episode of AOM was classified as severe or non-severe according to the child’s temperature and an ear ache score.

Comment: None.

QUESTION What are the effects of interventions to prevent recurrence of AOM in children?

OPTION ANTIBIOTIC PROPHYLAXIS (LONG TERM)

- For GRADE evaluation of interventions for AOM in children, see table, p 29.
- Long-term antibiotic prophylaxis may reduce recurrence rates; however, the possibility of adverse effects and antibiotic resistance should be taken into account.
- We do not know whether any one regimen should be used in preference to another to prevent recurrent attacks.

Benefits and harms

Antibiotic prophylaxis versus placebo:

We found one systematic review (13 RCTs, search date 2006), which compared antibiotics versus placebo or no treatment for the prevention of AOM, AOM with perforation, or chronic suppurative otitis media. [25]

Recurrence

Compared with placebo Prophylactic antibiotics are more effective at reducing the incidence of AOM compared with placebo or no treatment in children at risk of otitis media (high-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recurrence</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[25] Systematic review</td>
<td>1358 children at increased risk of AOM</td>
<td>Proportion of children with AOM or chronic suppurative otitis media 253/748 (34%) with antibiotics 331/610 (54%) with placebo or no treatment</td>
<td>RR 0.62 95% CI 0.52 to 0.75</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13 RCTs in this analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[25] Systematic review</td>
<td>1112 children at increased risk of AOM</td>
<td>Number of episodes of otitis media 360 episodes with antibiotics 752 episodes with placebo or no treatment</td>
<td>Incidence rate ratio (IRR) 0.48 95% CI 0.37 to 0.62; see further information on studies for definition of IRR Antibiotics prevented 1.5 episodes of AOM for every 12 months of treatment per child</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12 RCTs in this analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Symptoms of AOM
No data from the following reference on this outcome. [25]

Complications

No data from the following reference on this outcome. [25]

Adverse effects

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic review</td>
<td>714 children at increased risk of AOM 11 RCTs in this analysis</td>
<td>Adverse effects 10/405 (2%) with antibiotics 3/309 (1%) with placebo or no treatment</td>
<td>RR 1.99 95% CI 0.25 to 15.89</td>
<td>↔</td>
<td>Not significant</td>
</tr>
</tbody>
</table>

Further information on studies

The incidence rate ratio (IRR), also known as the rate ratio, is the incidence rate in the intervention group divided by the incidence rate in the placebo group.

Comment: Clinical guide:

We found insufficient evidence on which antibiotic to use and for how long, and on how many episodes of AOM to justify starting preventive treatment.

OPTION PNEUMOCOCCAL VACCINE

- For GRADE evaluation of interventions for AOM in children, see table, p 29.
- Vaccination in infancy with pneumococcal conjugate vaccine (PCV) has some effect on recurrent AOM.
- Vaccination with PCV in children aged 1 to 7 years with recurrent AOM has no effect on recurrences.
- The adverse effects associated with pneumococcal vaccination are unclear.
- Note
  We found no clinically important results from RCTs about the effects of the 23-valent pneumococcal vaccine that is currently available.

Benefits and harms

Pneumococcal vaccine versus placebo or control:

We found one systematic review (search date 2007). [26] The review included 7 RCTs on 7- to 11-valent pneumococcal conjugate vaccine (PCV) (with different carrier proteins). Owing to significant heterogeneity regarding study population, type of conjugate vaccine, and outcome measures, the review did not perform a meta-analysis. We therefore present results from individual RCTs.
Recurrence

Compared with placebo or control vaccine, pneumococcal conjugate vaccine (7- to 11-valent) may be more effective than placebo at reducing the incidence of AOM when administered during infancy, but may be no more effective when given to children aged 1 to 7 years with recurrent AOM (very low-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[26]</td>
<td>Systematic review</td>
<td>37,868 children aged 2 months Data from 1 RCT</td>
<td>Episodes, per person-year with vaccination with control vaccine Absolute results not reported Intention-to-treat analysis</td>
<td>Relative risk reduction (RRR) 6% 95% CI 4% to 8%</td>
<td>pneumococcal vaccine</td>
</tr>
<tr>
<td>[26]</td>
<td>Systematic review</td>
<td>1662 children aged 2 months Data from 1 RCT</td>
<td>Episodes, per person-year 1.16 with vaccination 1.24 with control vaccine Per-protocol analysis</td>
<td>RRR +6% 95% CI –4% to +16%</td>
<td>Not significant</td>
</tr>
<tr>
<td>[26]</td>
<td>Systematic review</td>
<td>4968 children aged 6 weeks to 5 months Data from 1 RCT</td>
<td>Episodes, per person-year 0.08 with vaccination 0.13 with control vaccine Per-protocol analysis</td>
<td>RRR 34% 95% CI 21% to 44%</td>
<td>pneumococcal vaccine</td>
</tr>
<tr>
<td>[26]</td>
<td>Systematic review</td>
<td>264 children aged 12 months to 35 months Data from 1 RCT</td>
<td>Episodes, per person-year 0.66 with vaccination 0.79 with control vaccine Intention-to-treat analysis</td>
<td>RRR +17% 95% CI –2% to +33%</td>
<td>Not significant</td>
</tr>
<tr>
<td>[26]</td>
<td>Systematic review</td>
<td>383 children aged 1 year to 7 years with recurrent AOM Data from 1 RCT</td>
<td>Episodes, per person-year 1.1 with vaccination 0.83 with control vaccine Intention-to-treat analysis</td>
<td>RRR –29% 95% CI –62% to –2%</td>
<td>control vaccine</td>
</tr>
<tr>
<td>[26]</td>
<td>Systematic review</td>
<td>74 children aged 1 year to 7 years with recurrent AOM Data from 1 RCT</td>
<td>Episodes, per person-year 0.78 with vaccination 0.67 with control vaccine Per-protocol analysis</td>
<td>RRR –16% 95% CI –96% to +31%</td>
<td>Not significant</td>
</tr>
<tr>
<td>[26]</td>
<td>Systematic review</td>
<td>37,868 children aged 2 months Data from 1 RCT</td>
<td>Recurrent AOM with vaccination with control vaccine Absolute results not reported Recurrent AOM was defined as at least 3 episodes in 6 months or at least 4 episodes in 1 year Intention-to-treat analysis</td>
<td>RRR 9% 95% CI 4% to 14%</td>
<td>pneumococcal vaccine</td>
</tr>
<tr>
<td>[26]</td>
<td>Systematic review</td>
<td>1662 children aged 2 months Data from 1 RCT</td>
<td>Recurrent AOM with vaccination with control vaccine</td>
<td>RRR +9% 95% CI –12% to +27%</td>
<td>Not significant</td>
</tr>
<tr>
<td>Ref (type)</td>
<td>Population</td>
<td>Outcome, Interventions</td>
<td>Results and statistical analysis</td>
<td>Effect size</td>
<td>Favours</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>------------------------</td>
<td>---------------------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>[26]</td>
<td>4968 children aged 6 weeks to 5 months Data from 1 RCT</td>
<td>Recurrent AOM with vaccination with control vaccine Absolute results not reported Recurrent AOM was defined as at least 3 episodes in 6 months or at least 4 episodes in 1 year Per-protocol analysis</td>
<td>RRR +56% 95% CI −2% to +81%</td>
<td>Not significant</td>
<td></td>
</tr>
</tbody>
</table>

**Symptoms of AOM**

No data from the following reference on this outcome. [26]

**Complications**

No data from the following reference on this outcome. [26]

**Adverse effects**

No data from the following reference on this outcome. [26]

**Further information on studies**

**Comment:**

Clinical guide:

Based on the current evidence, the review concluded that pneumococcal conjugate vaccine (PCV) is marginally beneficial in preventing AOM in infancy. The discrete reductions of 6% may, however, result in substantial reductions from a public health perspective. In most western countries, PCVs are implemented in national childhood vaccination programmes because of the effect on invasive pneumococcal infections. Administering PCVs in older children with a history of AOM has no effect on preventing further AOM episodes.

**OPTION**

**TYMPANOSTOMY (VENTILATION TUBES)**

- For GRADE evaluation of interventions for AOM in children, see table, p 29.
- Typanostomy with ventilation tube insertion leads to short-term reduction in the number of episodes of AOM, but it increases the risk of complications.
• We found limited evidence of only a short-term benefit from tympanostomy with ventilation tubes, with possibly increased risks of tympanosclerosis.

• Tympanostomy plus drainage tubes may increase the risk of tympanosclerosis and hearing impairment.

**Benefits and harms**

**Tympanostomy versus no surgery or myringotomy alone:**
We found one systematic review (search date 2008) [27] and one additional RCT. [28]

**Recurrence**

*Compared with no surgery or myringotomy alone* Tympanostomy plus insertion of drainage tubes may be more effective at reducing the incidence of AOM after 6 months, but not after 18 months (very low-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[27] Systematic review</td>
<td>148 children aged &lt;3 years 2 RCTs in this analysis</td>
<td>Proportion of children with at least 1 episode of AOM , 6 months 40/85 (47%) with tympanostomy 51/63 (81%) with control</td>
<td>OR 0.18 95% CI 0.08 to 0.42</td>
<td>⬤ ⬤ ⬤</td>
<td>tympanostomy</td>
</tr>
<tr>
<td>[28] RCT</td>
<td>44 children, aged 9 months to 7 years, with bilateral recurrent AOM of equal severity in each ear despite &gt;3 months of antibiotic prophylaxis</td>
<td>Mean number of episodes of AOM , 6 months 0.6% with tympanostomy tube insertion into a randomly selected ear 1.8% with contralateral ear receiving either no surgery or myringotomy alone</td>
<td>Difference in mean number of episodes: –1.2 95% CI –2.2 to –0.9</td>
<td>⬤ ⬤</td>
<td>tympanostomy</td>
</tr>
<tr>
<td>[28] RCT</td>
<td>44 children, aged 9 months to 7 years, with bilateral recurrent AOM of equal severity in each ear despite &gt;3 months of antibiotic prophylaxis</td>
<td>Mean number of episodes of AOM , 18 months 0.8% with tympanostomy tube insertion into a randomly selected ear 0.8% with contralateral ear receiving either no surgery or myringotomy alone</td>
<td>Difference in mean number of episodes 0% 95% CI –0.3 to +0.3</td>
<td>↔</td>
<td>Not significant</td>
</tr>
<tr>
<td>[28] RCT</td>
<td>44 children, aged 9 months to 7 years, with bilateral recurrent AOM of equal severity in each ear despite &gt;3 months of antibiotic prophylaxis</td>
<td>Recurrent ear infections with tympanostomy tube insertion into a randomly selected ear with contralateral ear receiving either no surgery or myringotomy alone</td>
<td>P = 0.3 The RCT reported a non-significant trend towards more recurrent infections and worse hearing in ears that had received tympanostomy tubes, which became apparent after tube extrusion</td>
<td>↔</td>
<td>Not significant</td>
</tr>
</tbody>
</table>

**Complications**

*Compared with no surgery or myringotomy alone* Tympanostomy plus insertion of drainage tubes may increase the risk of tympanosclerosis in children with AOM (low-quality evidence).
Favours

Effect
size

Results and statistical
analysis

Outcome, Interventions

Population

Ref (type)

Tympanosclerosis

RCT

[29]

44 children, aged 9 months to 7 years with bilateral recurrent AOM of equal severity in each ear despite >3 months of antibiotic prophylaxis

Tympanosclerosis

35/61 (57%) with tympanostomy tube

5/26 (19%) with myringotomy alone

P = 0.004

myringotomy alone

No data from the following reference on this outcome. [27]

Symptoms of AOM

No data from the following reference on this outcome. [27] [28]

Adverse effects

No data from the following reference on this outcome. [27] [28]

Further information on studies

The review included only studies that randomised children and excluded the RCT that randomised ears. [28]

Recurrent AOM was defined as the recurrent presence (>4 episodes) of ear ache with red and bulging tympanic membranes. Anatomical abnormalities (tympanosclerosis, atrophy, or retraction and chronic perforation), although not thought to be clinically significant, were more common in the ears receiving tympanostomy tubes. The RCT included some children with otitis media with effusion, although the results concerning benefits presented here refer only to those children in the study with recurrent AOM. It was not possible from the data available to differentiate the evidence on harms into children with recurrent AOM compared with otitis media with effusion. Medical treatment and antibiotic prophylaxis were allowed "whenever indicated". It was not possible from the data presented to tell whether the different groups differed in the amount of medical treatment and prophylactic antibiotics.

Comment: None.

OPTION INFLUENZA VACCINE

- For GRADE evaluation of interventions for AOM in children, see table, p 29.
- Influenza vaccination in healthy children has no effect on the incidence of AOM.
Benefits and harms

Influenza vaccine versus placebo:

We found one systematic review (search date 2007, 6 RCTs). [29]

Recurrence

Compared with placebo Influenza vaccine seems no more effective at preventing incidence of AOM in children aged 6 months to 7 years (moderate-quality evidence).

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[29] Systematic review</td>
<td>S253 children aged 6 months to 7 years</td>
<td>Incidence of AOM, 3 to 8 months 1249/3223 (39%) with influenza vaccination 832/2030 (41%) with placebo</td>
<td>RR 1.00, 95% CI 0.79 to 1.26, P = 0.99</td>
<td>←</td>
<td>Not significant</td>
</tr>
</tbody>
</table>

Symptoms of AOM

No data from the following reference on this outcome. [29]

Complications

No data from the following reference on this outcome. [29]

Adverse effects

No data from the following reference on this outcome. [29]

Further information on studies

Comment: The RCTs in the systematic review [28] included only healthy children; therefore, we can draw no firm conclusions about children with recurrent AOM.

OPTION XYLITOL SYRUP OR GUM

• For GRADE evaluation of interventions for AOM in children, see table, p 29.
• Xylitol must be given as prophylaxis, not as treatment.
• Xylitol chewing gum or syrup given 5 times daily has a small preventive effect on recurrence of AOM, but the compliance issues in giving a medicine to such young children 5 times daily render it an unrealistic treatment option.
• Xylitol is not effective when given 3 times daily or only during an acute respiratory tract infection.
Benefits and harms

Xylitol versus placebo:

We found no systematic review, but found 4 RCTs. \[30\] [31] [32] [33]

Recurrence

**Compared with placebo** Xylitol given 5 times daily, but not 3 times daily, may be more effective at reducing recurrence of AOM in children aged up to 7 years. Xylitol may be no more effective at reducing AOM recurrence when given only during an acute respiratory tract infection (low-quality evidence). **Note** The issues of compliance in giving a medicine to such young children 5 times daily render xylitol an unrealistic treatment option.

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recurrence of AOM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[30] RCT</td>
<td>306 children with recurrent AOM, mean age 5 years</td>
<td>Children with at least one episode of AOM, 2 months</td>
<td>ARR 8.7% 95% CI 0.4% to 17.0% P = 0.04</td>
<td></td>
<td>[+++]</td>
</tr>
<tr>
<td>[31] RCT 5-armed trial</td>
<td>857 children with recurrent AOM The remaining arms assessed xylitol chewing gum, control chewing gum, and xylitol lozenge</td>
<td>Incidence rate of AOM per person-years at risk, 3 months</td>
<td>Difference 1.02 95% CI 0.29 to 1.75 P = 0.006</td>
<td></td>
<td>[+++]</td>
</tr>
<tr>
<td>[31] RCT 5-armed trial</td>
<td>857 children with recurrent AOM The remaining arms assessed xylitol syrup, control syrup, and xylitol lozenges</td>
<td>Incidence rate of AOM per person-years at risk, 3 months</td>
<td>Difference 0.65 95% CI 0.14 to 1.16 P = 0.012</td>
<td></td>
<td>[+++]</td>
</tr>
<tr>
<td>[32] RCT 5-armed trial</td>
<td>1277 children with recurrent AOM during an acute respiratory tract infection The remaining arms assessed xylitol chewing gum, control chewing gum, and xylitol lozenges</td>
<td>Children with AOM, 3 weeks</td>
<td>ARR –0.1 95% CI –8.3 to +5.8 P = 0.72</td>
<td></td>
<td>←→</td>
</tr>
<tr>
<td>[32] RCT 5-armed trial</td>
<td>1277 children with recurrent AOM during an acute respiratory tract infection The remaining arms assessed xylitol syrup, control syrup, and xylitol lozenges</td>
<td>Children with AOM, 3 weeks</td>
<td>ARR –0.1 95% CI –9.4 to +3.2 P = 0.33</td>
<td></td>
<td>←→</td>
</tr>
</tbody>
</table>
### Symptoms of AOM

No data from the following reference on this outcome. [30] [31] [32] [33]

### Complications

No data from the following reference on this outcome. [30] [31] [32] [33]

### Adverse effects

No data from the following reference on this outcome. [30] [31] [32] [33]

### Further information on studies

**Comment:** Compliance is a potential problem with a medication that must be given 5 times a day to a young child. In addition, the preventing effect of xylitol is quite small — only one episode of AOM per year. For the time being, then, xylitol does not represent a realistic treatment option for AOM in children.

**GLOSSARY**

**High-quality evidence** Further research is very unlikely to change our confidence in the estimate of effect.

**Low-quality evidence** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Mastoiditis** The presence of infection in the mastoid cavity.

**Moderate-quality evidence** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Myringotomy** The surgical creation of a perforation in the tympanic membrane.

**Very low-quality evidence** Any estimate of effect is very uncertain.

**SUBSTANTIVE CHANGES**

**Influenza vaccine** New option added. Categorised as Unlikely to be beneficial.

**Xylitol syrup or gum** New option added. Categorised as Unlikely to be beneficial.

---

<table>
<thead>
<tr>
<th>Ref (type)</th>
<th>Population</th>
<th>Outcome, Interventions</th>
<th>Results and statistical analysis</th>
<th>Effect size</th>
<th>Favours</th>
</tr>
</thead>
<tbody>
<tr>
<td>[33] RCT</td>
<td>663 children with recurrent AOM, mean age 4.1 years</td>
<td>Incidence rate of AOM per person-years at risk, 3 months 2.09 with xylitol 1.83 with control Treatment and control given 3 times daily as either a chewing gum or syrup, depending on whether the child was old enough to chew gum</td>
<td>Difference $-0.26$ 95% CI $-0.71$ to $+0.19$ $P = 0.25$</td>
<td>$\rightarrow$</td>
<td>Not significant</td>
</tr>
</tbody>
</table>
Analgesics for AOM in children One Cochrane systematic review updated. [10] Categorisation unchanged (Likely to be beneficial).


Choice of antibiotic regimen New evidence added. [18] Categorisation unchanged (Trade-off between benefits and harms).

Immediate or delayed antibiotics for AOM in children New evidence added. [19] Categorisation unchanged (Trade-off between benefits and harms).

Longer versus shorter courses of antibiotics One Cochrane systematic review updated. [21] Categorisation unchanged (Trade-off between benefits and harms).

Tymanostomy (ventilation tubes) New evidence added. [27] Categorisation unchanged (Likely to be ineffective or harmful).

Pneumococcal vaccine New evidence added. [26] Categorisation changed from Unlikely to be beneficial to Likely to be beneficial.

REFERENCES

Competing interests: RD is the co-author of 4 systematic reviews referenced in this review. MMR was paid by GlaxoSmithKline for a presentation on the burden of otitis media at the ESPO in Budapest in 2008 and is co-author of 4 systematic reviews referenced in this review.

Disclaimer

The information contained in this publication is intended for medical professionals. Categories presented in Clinical Evidence indicate a judgement about the strength of the evidence available to our contributors prior to publication and the relevant importance of benefit and harms. We rely on our contributors to confirm the accuracy of the information presented and to adhere to describe accepted practices. Readers should be aware that professionals in the field may have different opinions. Because of this and regular advances in medical research we strongly recommend that readers’ independently verify specified treatments and drugs including manufacturers’ guidance. Also, the categories do not indicate whether a particular treatment is generally appropriate or whether it is suitable for a particular individual. Ultimately it is the readers’ responsibility to make their own professional judgements, so to appropriately advise and treat their patients. To the fullest extent permitted by law, BMJ Publishing Group Limited and its editors are not responsible for any losses, injury or damage caused to any person or property (including under contract, by negligence, products liability or otherwise) whether they be direct or indirect, special, incidental or consequential, resulting from the application of the information in this publication.
## GRADE Evaluation of interventions for AOM in children.

### Important outcomes

<table>
<thead>
<tr>
<th>Studies (Participants)</th>
<th>Outcome</th>
<th>Comparison</th>
<th>Type of evidence</th>
<th>Quality</th>
<th>Consistency</th>
<th>Directness</th>
<th>Effect size</th>
<th>GRADE</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>What are the effects of treatments for AOM in children?</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 (117) [10]</td>
<td>Symptoms of AOM</td>
<td>Topical anaesthetic versus placebo</td>
<td>4</td>
<td>–1</td>
<td>0</td>
<td>–1</td>
<td>0</td>
<td>Low</td>
<td>Quality point deducted for sparse data. Directness point deducted for inclusion of studies that included oral analgesics</td>
</tr>
<tr>
<td>1 (219) [11]</td>
<td>Symptoms of AOM</td>
<td>Oral analgesics versus placebo</td>
<td>4</td>
<td>–1</td>
<td>0</td>
<td>–1</td>
<td>0</td>
<td>Low</td>
<td>Quality point deducted for incomplete reporting of results. Directness point deducted for uncertain validity of outcome assessment</td>
</tr>
<tr>
<td>at least 19 (at least 3805) [13] [14] [15]</td>
<td>Symptoms of AOM</td>
<td>Antibiotics versus placebo</td>
<td>4</td>
<td>0</td>
<td>–1</td>
<td>–1</td>
<td>0</td>
<td>Low</td>
<td>Consistency point deducted for conflicting results. Directness point deducted for range of interventions included</td>
</tr>
<tr>
<td>6 (2153) [13]</td>
<td>Recurrence</td>
<td>Antibiotics versus placebo</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>1 (2287) [13] [14]</td>
<td>Complications</td>
<td>Antibiotics versus placebo</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>–1</td>
<td>0</td>
<td>Moderate</td>
<td>Directness point deducted for range of interventions included</td>
</tr>
<tr>
<td>at least 27 (at least 4580) [13] [9] [19]</td>
<td>Symptoms of AOM</td>
<td>Different antibiotics versus each other</td>
<td>4</td>
<td>–2</td>
<td>0</td>
<td>–2</td>
<td>0</td>
<td>Very low</td>
<td>Quality points deducted for incomplete reporting of results and heterogeneity of outcome measures and controls. Directness points deducted for range of participants and interventions included</td>
</tr>
<tr>
<td>2 (498) [19]</td>
<td>Symptoms of AOM</td>
<td>Immediate versus delayed antibiotic treatment</td>
<td>4</td>
<td>0</td>
<td>–1</td>
<td>0</td>
<td>0</td>
<td>Moderate</td>
<td>Consistency point deducted for conflicting results</td>
</tr>
<tr>
<td>27 (6727) [21]</td>
<td>Symptoms of AOM</td>
<td>Longer versus shorter course of antibiotics</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>1 (171) [22]</td>
<td>Symptoms of AOM</td>
<td>Myringotomy versus no myringotomy</td>
<td>4</td>
<td>–2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Low</td>
<td>Quality points deducted for sparse data and incomplete reporting of results</td>
</tr>
<tr>
<td>3 (821) [23] [22] [24]</td>
<td>Symptoms of AOM</td>
<td>Myringotomy versus antibiotics</td>
<td>4</td>
<td>–1</td>
<td>–1</td>
<td>0</td>
<td>0</td>
<td>Low</td>
<td>Quality point deducted for incomplete reporting of results. Consistency point deducted for conflicting results</td>
</tr>
<tr>
<td><strong>What are the effects of interventions to prevent recurrence of AOM in children?</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 (at least 1358) [25]</td>
<td>Recurrence</td>
<td>Antibiotic prophylaxis versus placebo</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>12 (46,457) [26]</td>
<td>Recurrence</td>
<td>Pneumococcal vaccine versus placebo or control</td>
<td>4</td>
<td>–2</td>
<td>–1</td>
<td>0</td>
<td>0</td>
<td>Very low</td>
<td>Quality points deducted for incomplete reporting and for no intention-to-treat analyses in many RCTs. Consistency point deducted for conflicting results</td>
</tr>
<tr>
<td>3 (192) [27] [28]</td>
<td>Recurrence</td>
<td>Tymanostomy versus no surgery or myringotomy alone</td>
<td>4</td>
<td>–2</td>
<td>–1</td>
<td>0</td>
<td>0</td>
<td>Very low</td>
<td>Quality points deducted for sparse data and incomplete reporting of results. Consistency point deducted for different results at different end points</td>
</tr>
<tr>
<td>1 (44) [28]</td>
<td>Complications</td>
<td>Tymanostomy versus no surgery or myringotomy alone</td>
<td>4</td>
<td>–1</td>
<td>–1</td>
<td>0</td>
<td>0</td>
<td>Low</td>
<td>Quality point deducted for sparse data. Consistency point deducted for different results at different end points</td>
</tr>
</tbody>
</table>
We initially allocate 4 points to evidence from RCTs, and 2 points to evidence from observational studies. To attain the final GRADE score for a given comparison, points are deducted or added from this initial score based on preset criteria relating to the categories of quality, directness, consistency, and effect size. Quality: based on issues affecting methodological rigour (e.g., incomplete reporting of results, quasi-randomisation, sparse data [<200 people in the analysis]). Consistency: based on similarity of results across studies. Directness: based on generalisability of population or outcomes. Effect size: based on magnitude of effect as measured by statistics such as relative risk, odds ratio, or hazard ratio.